In vitro and in vivo antibacterial activities of S-1090, a new oral cephalosporin.
S-1090, a new oral cephalosporin, was active against selected gram-negative bacteria and methicillin-susceptible clinical isolates of Staphylococcus aureus, Staphylococcus epidermidis, and Staphylococcus warneri, against which it had excellent activity. S-1090 was the most active compound against Streptococcus pyogenes and Streptococcus agalactiae among the agents compared. The in vivo efficacy of S-1090 against systemic and urinary and respiratory tract infections caused by gram-positive and -negative bacteria was superior to that expected from the in vitro and in vivo activities of the agents against which it was compared.
Tsuji
M
M
Department of Microbiology, Toho University School of Medicine, Tokyo, Japan.
Ishii
Y
Y
Ohno
A
A
Miyazaki
S
S
Yamaguchi
K
K
D000818:Animals; D016470:Bacteremia / Q000188:drug therapy / Q000382:microbiology / Q000517:prevention & control; D001419:Bacteria / Q000187:drug effects*; D001424:Bacterial Infections / Q000188:drug therapy / Q000382:microbiology / Q000517:prevention & control; D002511:Cephalosporins / Q000494:pharmacology* / Q000627:therapeutic use; D006090:Gram-Negative Bacteria / Q000187:drug effects; D006094:Gram-Positive Bacteria / Q000187:drug effects; D008297:Male; D051379:Mice; D008813:Mice, Inbred ICR; D008826:Microbial Sensitivity Tests; D012141:Respiratory Tract Infections / Q000188:drug therapy / Q000382:microbiology / Q000517:prevention & control; D014552:Urinary Tract Infections / Q000188:drug therapy / Q000382:microbiology
D002511:Cephalosporins; C098102:S 1090